Clarivate

AUGUST 2, 2022

Increased collaboration between regulatory agencies also appears to be having a positive impact on the roll out of new drugs. The following blog post summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2012-2021. N) = number of approvals.

Medicine 98

Medicine Food and Drug Administration FDA Healthcare 98

European Pharmaceutical Review

NOVEMBER 15, 2022

As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.” Takeaways from ISPE’s GAMP 5 Second Edition update.

Manufacturing 84

Manufacturing Pharma Food and Drug Administration Safety 84

World of DTC Marketing

MARCH 17, 2022

What treatment works in one patient may not work in another but we have to keep trying to beat cancer anyway we can. The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. ” There is also the issue of medical debt of surviving cancer patients.

Food and Drug Administration 255

Food and Drug Administration Medical Ethics Patients 255

pharmaphorum

SEPTEMBER 13, 2022

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). In 39-year-old patient Sarah Newbury, Solly observed the appearance of fatigue and bone pain resulting from multiple fractures.

Food and Drug Administration 88

Food and Drug Administration Patients Engineering Physicians 88

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 77

Food and Drug Administration Safety Patients Leads 77

Evolve Your Success

FEBRUARY 7, 2023

He discusses why the future of the healthcare industry in the United States lies not in hospital buildings but in surgery centers. The patients like that their copay is lower. Patients have a lower copay. One in insurance, retail and healthcare that is still around. It’s the first drug-eluting heart stent in the world.

Medical 52

Medical Sales Medical sales Doctors 52